Clinical Trials Logo

Clinical Trial Summary

Phase 2, Open label, dose escalation study of two dose cohorts of MABp1 in patients with moderate to severe atopic dermatitis. The study is multicenter, and will consist of two dose levels: MABp1 administered subcutaneously at a dose of 200 mg weekly (4 doses) and MABp1 administered subcutaneously at a dose of 400 mg weekly (4 doses). Patients will be followed for 6 weeks to allow for assessment of safety and preliminary efficacy.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03496974
Study type Interventional
Source XBiotech, Inc.
Contact Mark Williams, MD
Phone 737-207-4612
Email mwilliams@xbiotech.com
Status Recruiting
Phase Phase 2
Start date May 21, 2018
Completion date September 2018

See also
  Status Clinical Trial Phase
Completed NCT02595073 - Clinical Study to Evaluate the Efficacy and Safety of DSXS With Atopic Dermatitis Phase 3
Withdrawn NCT03089476 - Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy N/A
Not yet recruiting NCT03441568 - In-home Use Test of the New Modified Diprobase Formulation to Assess the Safety and Tolerability in Infants and Children Under Physician's Control N/A
Completed NCT03304470 - A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis Phase 2
Recruiting NCT02910791 - The Role of Bacterial Toxins in Human Skin Disease N/A
Recruiting NCT03051347 - Asthma and Atopic Dermatitis Validation of PROMIS Pediatric Instruments N/A
Completed NCT02844452 - Antipruritic Effect of Acupuncture in Patients With Atopic Dermatitis N/A
Completed NCT02865356 - Topical Solution for the Treatment of Atopic Dermatitis Phase 2
Completed NCT02914548 - Study of OPA-15406 Ointment in Patients With Atopic Dermatitis Phase 2
Completed NCT02260986 - Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis Phase 3
Withdrawn NCT01936194 - The Effects of Polyunsaturated Fatty Acids (PUFA) on Allergic/Atopic Dermatitis N/A
Completed NCT01927705 - Safety and Efficacy of FURESTEM-AD Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis (AD) Phase 1/Phase 2
Recruiting NCT01692093 - KM110329 in Adult Patients With Atopic Dermatitis Phase 2
Terminated NCT01447758 - Safety, Tolerability and Pharmacokinetics of LEO 29102 Cream in Atopic Dermatitis. Phase 1
Completed NCT01223222 - A Study to Evaluate Safety, Tolerability and Efficacy of Lytixar™ (LTX-109) on Uncomplicated, Gram-positive, Skin Infection Phase 2
Completed NCT02094287 - Placebo Effect in the Treatment of Atopic Dermatitis N/A
Completed NCT01179880 - A Study of E6005 in Japanese Patients With Atopic Dermatitis Phase 1/Phase 2
Completed NCT00958516 - Assessment of the Phototoxic Potential of LEO 29102 Cream Phase 1
Completed NCT00985894 - Comparison Between Asynchronous Online Care Model With Usual In Office Care for the Management of Atopic Dermatitis N/A
Completed NCT01177566 - Pimecrolimus Cream 1% (Elidel®) and Medicated Device Cream (EletoneTM) in the Treatment and Maintenance of Atopic Dermatitis. Phase 4